Table 3.
Estimate (95% CI) | P | |
---|---|---|
Long-term survivor model (HR) | ||
TT1 (ref.) | ||
TT2− | 0.85 (0.48–1.49) | 0.57 |
TT2+ | 0.50 (0.18–0.79) | 0.003 |
TT3 | 0.18 (0.10–0.31) | <0.001 |
Age | 1.13 (0.995–1.03) | 0.16 |
Cytogenetic abnormalities | 1.17 (1.07–2.14) | 0.019 |
Short-term survival model (HR) | ||
TT1 (ref.) | ||
TT2− | 0.51 (0.88–1.53) | 0.66 |
TT2+ | 0.72 (0.39–1.32) | 0.29 |
TT3 | 1.72 (0.90–3.29) | 0.10 |
Age | 1.00 (0.98–1.02) | 0.80 |
Cytogenetic abnormalities | 1.18 (0.80–1.75) | 0.40 |